Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

Terumo Company

4543.T
JP3546800008
867003

Price

2,873.15
Today +/-
-0.26
Today %
-1.46 %
P

Terumo stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Terumo stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Terumo stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Terumo stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Terumo's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Terumo Stock Price History

DateTerumo Price
10/25/20242,873.15 undefined
10/24/20242,915.50 undefined
10/23/20242,886.50 undefined
10/22/20242,915.50 undefined
10/21/20242,945.00 undefined
10/18/20242,936.50 undefined
10/17/20242,898.00 undefined
10/16/20242,918.50 undefined
10/15/20242,942.50 undefined
10/11/20242,950.50 undefined
10/10/20242,943.50 undefined
10/9/20242,931.50 undefined
10/8/20242,900.50 undefined
10/7/20242,843.50 undefined
10/4/20242,813.50 undefined
10/3/20242,754.50 undefined
10/2/20242,726.50 undefined
10/1/20242,727.00 undefined
9/30/20242,700.00 undefined
9/27/20242,854.00 undefined
9/26/20242,705.00 undefined

Terumo Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Terumo, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Terumo from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Terumo’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Terumo. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Terumo’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Terumo’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Terumo’s growth potential.

Terumo Revenue, EBIT and net profit per share

DateTerumo RevenueTerumo EBITTerumo Net Income
2027e1.18 T undefined225.23 B undefined173.13 B undefined
2026e1.09 T undefined191.9 B undefined148.79 B undefined
2025e1.03 T undefined166.65 B undefined130.08 B undefined
2024921.86 B undefined143.03 B undefined106.37 B undefined
2023820.21 B undefined119.79 B undefined89.33 B undefined
2022703.3 B undefined116.66 B undefined88.81 B undefined
2021613.84 B undefined97.44 B undefined77.27 B undefined
2020628.9 B undefined108.59 B undefined85.21 B undefined
2019599.48 B undefined99.05 B undefined79.47 B undefined
2018587.78 B undefined106.13 B undefined91.3 B undefined
2017514.16 B undefined89.87 B undefined55 B undefined
2016525.03 B undefined81.7 B undefined50.68 B undefined
2015489.51 B undefined67.46 B undefined38.47 B undefined
2014467.36 B undefined65.29 B undefined34.1 B undefined
2013402.29 B undefined53.22 B undefined47.01 B undefined
2012386.69 B undefined63.05 B undefined24.17 B undefined
2011328.21 B undefined62.61 B undefined32.34 B undefined
2010316.01 B undefined63.28 B undefined40.72 B undefined
2009302.75 B undefined54.04 B undefined36.88 B undefined
2008306.38 B undefined66.94 B undefined43.38 B undefined
2007276.44 B undefined58.46 B undefined37.23 B undefined
2006247.05 B undefined48.25 B undefined32.33 B undefined
2005230 B undefined44.93 B undefined26.98 B undefined

Terumo Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (T)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
19911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
0.110.110.110.110.110.120.140.150.160.170.180.190.20.220.230.250.280.310.30.320.330.390.40.470.490.530.510.590.60.630.610.70.820.921.031.091.18
-1.742.79-2.823.225.5913.478.217.916.532.846.277.247.266.887.4111.9010.83-1.194.383.8617.824.0416.174.747.26-2.0714.321.994.91-2.3914.5716.6212.3911.206.648.06
43.4741.4344.9246.3749.4950.8452.6152.4851.4551.0649.4348.2549.1751.2553.8154.9255.4754.9052.2752.6452.0452.9251.1351.7852.3053.8753.2654.3354.4654.6953.2152.5250.8951.98---
47.646.1551.4351.5956.8561.6572.3978.1482.6687.487.0390.2798.65110.29123.77135.67153.33168.2158.24166.35170.8204.64205.69242.01256.03282.86273.84319.33326.5343.93326.62369.34417.37479.18000
4.933.269.6912.1114.2618.1823.1224.630.2529.1528.828.0427.836.6544.9348.2558.4666.9454.0463.2862.6163.0553.2265.2967.4681.789.87106.1399.05108.5997.44116.66119.79143.03166.65191.9225.23
4.502.938.4610.8812.4214.9916.8016.5218.8217.0316.3614.9913.8617.0319.5319.5321.1521.8517.8520.0319.0816.3013.2313.9713.7815.5617.4818.0616.5217.2715.8716.5914.6015.5116.2617.5519.07
-1.5-7.690.50.673.913.2112.4614.3414.846.2816.6414.4418.0119.6526.9832.3337.2343.3836.8840.7232.3424.1747.0134.138.4750.685591.379.4785.2177.2788.8189.33106.37130.08148.79173.13
-413.14-106.5134.13481.70-18.01288.7715.103.44-57.64164.80-13.2224.709.1337.2919.8215.1816.52-14.9910.42-20.59-25.2794.54-27.4812.8331.738.5465.98-12.957.22-9.3214.940.5819.0922.2914.3816.35
-------------------------------------
-------------------------------------
0.760.760.760.760.760.780.830.840.850.840.840.840.810.80.790.810.810.790.770.760.760.760.760.760.780.80.770.760.760.761.511.511.51.49000
-------------------------------------
Details

Keystats

Revenue and Growth

The Terumo Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Terumo is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (T)TOTAL ASSETS (T)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (B)EQUITY (T)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (T)
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                                   
52.2634.5332.3830.1135.4829.0140.4123.3739.8532.140.2632.7331.6141.5357.5647.9644.5487.3457.0790.183.7978.7778.295.62179.68149.67105.39168.18124.71167.11200.83205.31187.38206.35
27.422.8717.7817.5921.9330.3242.6147.0248.7452.1658.2659.3856.2357.1959.8263.0369.1668.2566.1371.1175.7590.5693.79100.13103.49103.04108.08116.67124.29125.24125.91132.7144.17169.95
000000000000000000000000003.765.264.178.233.374.089.3810.1
19.719.0316.616.5215.8517.6319.7921.722.9227.1731.1736.834.9933.5934.7840.9445.6348.7454.5955.0657.6769.2885.1893.96101.4796.45106.05112.06134.11147.15175.58198.54249.62286.6
3.013.452.562.712.893.134.63.634.714.745.517.079.0710.259.3413.5612.2513.7415.8614.1619.2918.2629.7921.2827.8225.597.668.8711.4512.8718.2818.0920.8449.12
102.3779.8769.3266.9276.1580.08107.4195.72116.23116.17135.2135.98131.91142.56161.5165.49171.57218.07193.66230.43236.51256.87286.96310.99412.46374.75330.93411.04398.72460.61523.97558.71611.4722.12
111.1107.99100.490.0383.8380.2187.97101.31110.67116.79117.21119.48113.42109.41107.04109.84115.64112.74111.06114.03113.06131.75144.82157.76178.5175.79172.64179.22201.99264.41299.68333.86370.87415.85
5.7118.7926.8726.9323.513.7311.2511.8412.3212.411.447.616.910.510.1532.1634.840.5323.6938.8728.920.3930.337.9545.4637.7218.219.1821.622.3823.0925.9525.4338.78
3.273.273.273.273.273.273.273.713.563.423.28000000000000000000000.782.920
1.031.030.950.951.221.181.351.771.751.661.952.462.883.274.445.795.484.925.927.146.54131.98147.31150.6165146.81252.82236.37244.69241.86245.25264.12270.51285.88
0000000004.424.675.3719.8818.0718.4836.1835.0530.226.8222.9920.19138.81149.32154.16166.99143.71218.79208.07224.2219.64226.58250.68267.71302.35
6.755.346.077.285.493.614.654.726.0818.277.9113.8413.210.0510.835.194.64.4517.9112.0514.8412.7212.3221.3623.6722.9129.5827.1729.632.4632.6240.3756.3366.44
0.130.140.140.130.120.10.110.120.130.160.150.150.160.150.150.190.20.190.190.20.180.440.480.520.580.530.690.670.720.780.830.920.991.11
0.230.220.210.20.190.180.220.220.250.270.280.280.290.290.310.350.370.410.380.430.420.690.770.830.990.91.021.081.121.241.351.471.611.83
                                                                   
19.3119.3219.3219.3219.3219.3219.3228.9438.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.7238.72
32.7232.7332.7332.7332.7332.7332.7342.3452.152.152.152.152.152.152.159.0359.0359.0359.0359.0359.0352.152.152.152.150.9353.1952.4552.0351.8651.8351.9251.7651.75
35.5527.0328.9831.6133.8431.8242.0454.5167.5171.986.6499.18114.74131.88155.5183.39215.21252.67282.06316.7342.97290.53329.19353.62383.4419.76513.89589.6647706.51775.79847.69874.93955.34
0000000000-5.18-2.41-4-8.24-6.83-1.750.73-7.87-19.82-23.05-26.71-29.0210.140.5685.4349.77-7.12-30.89-10.34-30.45-5.1777.74155.34289.27
000000000000.09-0.641.961.887.378.955.03-5.122.34-1.92-0.057.4611.2716.9101.691.993.022.282.342.481.864.45
0.090.080.080.080.090.080.090.130.160.160.170.190.20.220.240.290.320.350.350.390.410.350.440.50.580.560.60.650.730.770.861.021.121.34
17.616.0315.4914.6113.7816.2617.8417.8517.7920.5119.9120.4919.7620.8921.8123.8625.7327.2527.8127.3730.7133.9237.5238.1538.4836.2938.4542.1843.8547.4746.6546.2555.5649.31
4.024.23.834.384.815.075.226.043.853.914.024.144.274.164.534.324.64.974.935.065.155.184.944.965.76.0449.8854.0953.9958.2364.5574.0188.22104.74
10.0410.626.459.297.418.7722.4420.0422.0222.9324.1627.8525.9529.230.4534.7235.3347.2435.647.0842.6958.4851.372.6979.7766.3533.9535.3144.3550.1451.850.6156.260.89
30.9530.0822.0820.6612.3513.8926.2222.823.422.3421.0119.928.1316.318.543.980.243525.192006018.050.260.360.061200040.320000
0014.422.614.784.1423.1520.550010.0510.050.540.635.320000.160.220.290.424.0444.885.6360.17.8547.440.7315.6948.386.8618.02164.22
62.6160.9362.2851.5453.1348.1394.8787.2967.0669.6979.1482.4278.6571.1970.6566.8765.89114.4593.799.7378.84158115.84160.94129.95168.84250.14179.01142.91211.85211.37177.72218379.15
71.8867.5555.5152.5247.2843.4920.770202010.10.066.325.53000.4400.410.460.64131159.15117.07219.65159.34210.34288.78225.14222.01244.7252.15248.65104.33
0000000000000.440.410.480.091.650.040.10.040.3844.7449.6647.850.0145.0840.0924.1224.320.3615.9612.758.873.03
8.168.748.077.677.176.616.185.985.2220.6720.0922.3418.2521.6421.4214.329.927.566.688.134.726.258.4710.7718.9416.8830.1838.730.3332.2622.518.7615.6517.81
80.0476.2963.5760.1954.4650.126.955.9825.2240.6730.1922.3925.0127.5721.914.41127.597.198.635.73181.99217.28175.63288.6221.31280.6351.6279.77274.63283.16283.66273.16125.16
142.64137.22125.85111.73107.5898.23121.8293.2792.28110.36109.33104.81103.6598.7692.5581.2977.89122.05100.89108.3684.58339.98333.12336.57418.55390.14530.74530.61422.68486.47494.53461.38491.16504.31
0.230.220.210.20.190.180.220.220.250.270.280.290.30.320.330.370.40.470.460.50.50.690.770.8310.951.131.181.151.261.361.481.611.84
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Terumo provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Terumo's financial health and stability.

Assets

Terumo's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Terumo must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Terumo after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Terumo's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
11.2829.0124.833.5133.7443.6551.5957.0765.3552.3563.4151.5649.6552.2952.9164.0576.9274.88106.63102.71106.4797.06114.5116.14
13.2614.0714.2918.2214.8817.7615.1815.5117.8120.3819.9120.3928.8432.5539.8830.3644.6734.4742.0444.0452.3653.9358.8870.24
000000000000000000000000
-12,864-18,157-18,169-11,759-10,663-18,878-20,123-24,399-9,001-40,328-16,853-31,836-32,772-30,57079-37,086-42,135-39,005-36,445-52,935-42,975-32,768-35,328-72,431
16.080.37.65-3.143.541.19-3.27-5.06-4.48-0.790.896.7110.49-43.395.460.8412.542.34-0.241.633.263.413.59
0.770.880.740.610.360.330.290.170.240.290.180.060.681.331.521.281.451.321.131.120.961.061.311.37
12.1111.4613.6314.9911.7518.1518.5719.8112.7929.3314.9526.0620.2124.322.883136.4525.5224.1230.2524.7723.0830.4927.66
27.7525.2228.5736.8241.543.7243.3843.1269.6831.6267.3546.8256.250.2796.2673.1180.382.89114.5693.57117.48121.49141.47117.54
-20,026-15,326-13,602-13,469-12,510-12,820-15,526-17,649-16,407-20,241-19,716-22,233-24,265-32,474-44,893-41,025-32,912-38,601-41,322-54,364-83,484-83,124-74,105-72,173
-32,455-14,144-15,419-31,720-11,638-15,635-54,389-19,915-28,069-23,987-25,272-18,986-247,182-31,293-52,744-40,421-23,495-183,517-44,105-74,792-84,714-85,317-78,454-59,121
-12.431.18-1.82-18.250.87-2.82-38.86-2.27-11.66-3.75-5.563.25-222.921.18-7.850.69.42-144.92-2.78-20.43-1.23-2.19-4.3513.05
000000000000000000000000
-0.41-1.59-11.445.15-11.82-8.82-10.19-3.3634.35-10.22-5.39-20.28189.64-13.98-22.0958.15-5.91119.6311.58-48.1134.3613.72-47.42-8.57
-00.01-7.83-8.63-4.89-0.1514.97-20-25.34-18.01-0.02-0.06-0.01-0.01-0.01-3.01-61-44.23-0.01-0.01-0-0-0-50.09
-2.2-3.37-21.05-5.98-19.21-12.340.37-28.643.08-34.82-11.49-26.42182.98-22.34-31.7944.12-79.9460.99-4.13-67.5414.01-7.44-70.88-86.56
000000000000-20-2-3179107135134158-1-1-1
-1,792-1,792-1,792-2,501-2,504-3,372-4,410-5,278-5,928-6,593-6,076-6,076-6,645-8,354-9,683-11,012-13,200-14,518-15,839-19,555-20,507-21,155-23,455-27,900
-7.758.16-7.53-1.119.9216.03-9.59-4.9142.33-30.3129.81-2.22-8.871.3717.3384.16-29.73-41.8862.79-44.8543.9233.874.48-17.93
7,7279,89614,96523,35428,98530,90427,85425,47453,27311,37447,63424,59031,93617,79551,36532,08647,39144,28973,23939,20733,99538,36167,36245,363
000000000000000000000000

Terumo stock margins

The Terumo margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Terumo. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Terumo.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Terumo's sales revenue. A higher gross margin percentage indicates that the Terumo retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Terumo's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Terumo's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Terumo's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Terumo. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Terumo's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Terumo Margin History

Terumo Gross marginTerumo Profit marginTerumo EBIT marginTerumo Profit margin
2027e51.98 %19.07 %14.66 %
2026e51.98 %17.55 %13.61 %
2025e51.98 %16.26 %12.69 %
202451.98 %15.51 %11.54 %
202350.89 %14.6 %10.89 %
202252.52 %16.59 %12.63 %
202153.21 %15.87 %12.59 %
202054.69 %17.27 %13.55 %
201954.46 %16.52 %13.26 %
201854.33 %18.06 %15.53 %
201753.26 %17.48 %10.7 %
201653.87 %15.56 %9.65 %
201552.3 %13.78 %7.86 %
201451.78 %13.97 %7.3 %
201351.13 %13.23 %11.69 %
201252.92 %16.3 %6.25 %
201152.04 %19.08 %9.85 %
201052.64 %20.03 %12.89 %
200952.27 %17.85 %12.18 %
200854.9 %21.85 %14.16 %
200755.47 %21.15 %13.47 %
200654.92 %19.53 %13.08 %
200553.81 %19.53 %11.73 %

Terumo Stock Sales Revenue, EBIT, Earnings per Share

The Terumo earnings per share therefore indicates how much revenue Terumo has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Terumo earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Terumo's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Terumo’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Terumo's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Terumo Revenue, EBIT and net profit per share

DateTerumo Sales per ShareTerumo EBIT per shareTerumo Earnings per Share
2027e795.56 undefined0 undefined116.59 undefined
2026e736.2 undefined0 undefined100.21 undefined
2025e690.36 undefined0 undefined87.61 undefined
2024619.36 undefined96.09 undefined71.47 undefined
2023546.12 undefined79.76 undefined59.48 undefined
2022464.74 undefined77.09 undefined58.69 undefined
2021405.57 undefined64.38 undefined51.05 undefined
2020830.75 undefined143.44 undefined112.56 undefined
2019790.79 undefined130.66 undefined104.83 undefined
2018777.22 undefined140.33 undefined120.72 undefined
2017664.36 undefined116.13 undefined71.07 undefined
2016654.98 undefined101.93 undefined63.22 undefined
2015630.8 undefined86.93 undefined49.57 undefined
2014614.95 undefined85.91 undefined44.86 undefined
2013529.33 undefined70.02 undefined61.86 undefined
2012508.8 undefined82.96 undefined31.8 undefined
2011431.86 undefined82.38 undefined42.55 undefined
2010415.8 undefined83.27 undefined53.58 undefined
2009393.69 undefined70.27 undefined47.96 undefined
2008388.81 undefined84.95 undefined55.05 undefined
2007343.4 undefined72.62 undefined46.25 undefined
2006306.51 undefined59.87 undefined40.11 undefined
2005290.04 undefined56.66 undefined34.02 undefined

Terumo business model

Terumo Corporation is a Japanese company that was founded in 1921. The company is headquartered in Tokyo and specializes in the development, manufacturing, and marketing of medical products and devices. It has a global presence and employs approximately 28,000 people in over 160 countries. The company's history began with the establishment of a small medical device company called Sekisen Kenonsha, founded by a group of doctors. In 1942, the company merged with another company named Terumo Sougou Kenkyuusho and became Terumo Corporation. Since then, the company has continuously expanded and diversified its product range. Terumo's business model focuses on providing solutions to improve people's health worldwide through the development of innovative medical devices and products. The company operates in three main business areas: 1. Interventional Systems: This business area specializes in the development of catheters, stent systems, and other medical products for cardiac, peripheral, and vascular interventions. 2. Blood Systems: This business area offers a wide range of products for blood collection and processing, including disposable syringes for blood collection and venous and arterial access systems. 3. Biosciences: This business area focuses on the development of products for cell culture and regenerative medicine, including stem cell therapy and cell banks for research. Terumo distributes its products not only directly to hospitals and medical facilities but also collaborates closely with distributors and partners to reach a wider customer base. Additionally, the company invests significant resources in research and development to continuously expand its product range. Among the products that Terumo offers, some of the most advanced and innovative medical devices on the market can be found. One example is the state-of-the-art catheters and stent systems that enable doctors to perform minimally invasive procedures to treat serious cardiovascular diseases. Terumo also produces disposable syringes that are widely used due to their high quality and reliability. In recent years, Terumo has also invested in regenerative medicine by developing products for cell culture and therapy. This includes stem cell therapy products that can be used in the treatment of certain cancers and blood disorders. Overall, Terumo Corporation has a long history as one of the leading companies in the medical technology industry. With its innovative products and strong focus on research and development, the company will continue to play an important role in improving the health and well-being of people worldwide. Terumo is one of the most popular companies on Eulerpool.com.

Terumo SWOT Analysis

Strengths

Terumo Corp is a leading medical equipment company with a strong global presence and a diverse product portfolio catering to various healthcare needs. Its strengths include:

  • Advanced technology and innovation capabilities, contributing to the development of cutting-edge medical devices.
  • Established brand reputation, known for its high-quality products and commitment to patient safety.
  • Extensive distribution network, enabling global market reach and penetration.
  • Strong research and development capabilities, fostering continuous product improvement and new product launches.

Weaknesses

Despite its strengths, Terumo Corp also faces certain weaknesses that need to be addressed in order to maintain competitiveness:

  • Reliance on a limited number of key suppliers for critical components, posing potential supply chain risks.
  • High production costs due to in-house manufacturing processes, impacting profit margins.
  • Complex regulatory environment in some regions, requiring significant compliance efforts.
  • Limited market share in certain product segments, hampering potential revenue growth.

Opportunities

Terumo Corp can explore the following opportunities to capitalize on the evolving healthcare landscape:

  • Rising demand for minimally invasive surgical procedures, creating a market for specialized medical devices.
  • Increasing prevalence of chronic diseases, leading to growing demand for monitoring and treatment devices.
  • Expansion into emerging markets with underserved healthcare infrastructure, presenting potential for market growth.
  • Collaboration with healthcare providers and research institutions to identify unmet needs and develop customized solutions.

Threats

Terumo Corp should be aware of the following threats that may impact its business and market position:

  • Intense competition from established players and new entrants in the medical equipment industry.
  • Stringent regulatory requirements, which may increase compliance costs and time-to-market for new products.
  • Economic downturns or healthcare budget cuts in key markets, potentially affecting product demand.
  • Rapid technological advancements and disruptive innovations, requiring continuous adaptation and investment.

Terumo Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Terumo historical P/E ratio, EBIT multiple, and P/S ratio

Terumo shares outstanding

The number of shares was Terumo in 2023 — This indicates how many shares 1.502 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Terumo earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Terumo's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Terumo’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Terumo's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Terumo stock splits

In Terumo's history, there have been no stock splits.

Terumo dividend history and estimates

In 2023, Terumo paid a dividend amounting to 43 JPY. Dividend means that Terumo distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Terumo provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Terumo’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Terumo's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Terumo Dividend History

DateTerumo Dividend
2027e24.92 undefined
2026e24.95 undefined
2025e24.91 undefined
202424 undefined
202343 undefined
202237 undefined
202131 undefined
202028 undefined
201927.5 undefined
201827 undefined
201722.5 undefined
201620 undefined
201517.5 undefined
201414.5 undefined
201312.75 undefined
201211 undefined
20116.25 undefined
20108 undefined
20098 undefined
20088.5 undefined
20077.5 undefined
20065.5 undefined
20054.5 undefined

Terumo dividend payout ratio

In 2023, Terumo had a payout ratio of 49.55%. The payout ratio indicates the percentage of the company's profits that Terumo distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Terumo represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Terumo could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Terumo's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Terumo Payout Ratio History

DateTerumo Payout ratio
2027e56.42 %
2026e54.7 %
2025e56.79 %
202457.77 %
202349.55 %
202263.05 %
202160.72 %
202024.88 %
201926.23 %
201822.37 %
201731.66 %
201631.64 %
201535.31 %
201432.32 %
201320.61 %
201234.6 %
201114.69 %
201014.93 %
200916.68 %
200815.44 %
200716.22 %
200613.71 %
200513.23 %
Unfortunately, there are currently no price targets and forecasts available for Terumo.

Terumo latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202418.78 22.82  (21.51 %)2025 Q1
3/31/202417.67 17.84  (0.91 %)2024 Q4
12/31/202319.97 20.03  (0.32 %)2024 Q3
9/30/202316.59 18.49  (11.46 %)2024 Q2
6/30/202317.83 15.14  (-15.1 %)2024 Q1
3/31/202333.65 25.71  (-23.6 %)2023 Q4
12/31/202236.21 39.97  (10.38 %)2023 Q3
9/30/202237.16 23.75  (-36.07 %)2023 Q2
6/30/202230.71 29.61  (-3.58 %)2023 Q1
3/31/202226.11 22.63  (-13.31 %)2022 Q4
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Terumo stock

Eulerpool World ESG Rating (EESG©)

91/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

75

Environment

Scope 1 - Direct Emissions
66,667
Scope 2 - Indirect emissions from purchased energy
191,637
Scope 3 - Indirect emissions within the value chain
1,444,050
Total CO₂ emissions
258,304
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees18.1
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Terumo shareholders

%
Name
Stocks
Change
Date
7.26764 % Nomura Asset Management Co., Ltd.107,914,158-805,9003/31/2024
4.22721 % The Dai-ichi Life Insurance Company, Limited62,768,000-1,010,0009/30/2023
3.59949 % Nikko Asset Management Co., Ltd.53,447,304-53,4003/31/2024
3.48500 % Daiwa Asset Management Co., Ltd.51,747,230-199,6403/31/2024
3.28947 % Meiji Yasuda Life Insurance Company48,844,00009/30/2023
2.92507 % The Vanguard Group, Inc.43,433,09224,4003/31/2024
2.90452 % Asset Management One Co., Ltd.43,128,000-5,093,4004/14/2023
2.61674 % BlackRock Institutional Trust Company, N.A.38,854,860416,2003/31/2024
2.38396 % Mitsubishi UFJ Trust and Banking Corporation35,398,400-8,602,16010/9/2023
2.08609 % Mitsubishi UFJ Kokusai Asset Management Co., Ltd.30,975,4001,785,40010/9/2023
1
2
3
4
5
...
10

Terumo Executives and Management Board

Mr. Shinjiro Sato63
Terumo President, Chief Executive Officer, Representative Director (since 2010)
Compensation 169 M
Mr. Toshiaki Takagi64
Terumo Chairman of the Board, Representative Director (since 2010)
Compensation 131 M
Mr. Naoki Muto60
Terumo Executive Officer, Chief Accounting & Financial Officer
Mr. Itaru Sakaguchi
Terumo Senior Executive Officer, Chief Operating Officer (COO) of Cardiovascular Company TIS Business, President of Subsidiary
Mr. Tomoko Adachi
Terumo Chief Human Resource Officer, Executive Officer
1
2
3
4
5
...
7

Most common questions regarding Terumo

What values and corporate philosophy does Terumo represent?

Terumo Corp represents values and a corporate philosophy centered around improving patient care and contributing to society. With a commitment to innovation, the company strives to provide high-quality medical products and services. Terumo Corp emphasizes integrity, teamwork, and continuous improvement in its operations. By leveraging its expertise in medical technology, the company aims to tackle healthcare challenges and enhance the well-being of individuals worldwide. Terumo Corp's dedication to patient-centric healthcare solutions and its focus on ethical practices make it a trusted leader in the medical industry.

In which countries and regions is Terumo primarily present?

Terumo Corp is primarily present in Japan, where it is headquartered. In addition to its domestic market, Terumo Corp has a strong presence in various countries and regions around the world. The company has established subsidiaries and affiliates in the United States, Europe, Asia-Pacific, the Middle East, and Latin America. Terumo Corp's global footprint enables it to cater to the healthcare needs of a diverse consumer base, making it a leading player in the global medical devices industry.

What significant milestones has the company Terumo achieved?

Terumo Corp, a leading healthcare solutions company, has achieved several significant milestones. With a history spanning over 100 years, Terumo Corp has consistently demonstrated innovation and growth. Some notable achievements include the development of the world's first hollow fiber oxygenator and the creation of advanced interventional systems like the Radial Artery Approach Kit. Terumo Corp has also expanded globally, establishing a strong presence in various markets and collaborating with healthcare providers worldwide. These milestones showcase Terumo Corp's commitment to improving patient care and further solidify its position as a leader in the healthcare industry.

What is the history and background of the company Terumo?

Terumo Corp. is a leading global medical device company specializing in the development and manufacturing of medical equipment and supplies. Founded in 1921 in Japan, Terumo has a rich history of innovation and growth. The company initially focused on the production of clinical thermometers and expanded over the years to produce a wide range of medical devices, including catheters, syringes, and cardiovascular systems. Today, Terumo Corp. is recognized for its expertise in areas such as cardiac and vascular surgeries, infusion therapy, and blood management. With a commitment to improving patient outcomes, Terumo continues to advance medical technology and provide innovative solutions for healthcare professionals worldwide.

Who are the main competitors of Terumo in the market?

The main competitors of Terumo Corp in the market include Becton, Dickinson and Company (BD), Johnson & Johnson, and Medtronic. These companies compete with Terumo Corp primarily in the field of medical devices and healthcare products. However, Terumo Corp differentiates itself through its innovative product offerings, strong global presence, and cutting-edge technologies. Despite facing competition from these industry leaders, Terumo Corp has established a strong market position and continues to strive for excellence in providing quality healthcare solutions.

In which industries is Terumo primarily active?

Terumo Corp is primarily active in the healthcare industry.

What is the business model of Terumo?

Terumo Corp, a leading global medical device company, operates based on a business model centered around healthcare solutions. They are dedicated to providing innovative medical products and services to enhance patient care and contribute to medical advancements. Terumo focuses on a wide range of healthcare areas, including cardiovascular, blood management, diabetes care, and general hospital supplies. With a customer-centric approach, Terumo emphasizes quality, safety, and research-driven solutions to meet the evolving needs of healthcare professionals and patients worldwide. Through their commitment to excellence, Terumo Corp continues to make significant contributions in improving medical outcomes and enhancing the overall healthcare experience.

What is the P/E ratio of Terumo 2024?

The Terumo P/E ratio is 40.2.

What is the P/S ratio of Terumo 2024?

The Terumo P/S ratio is 4.64.

What is the Quality Investing of Terumo?

The Quality Investing for Terumo is 8/10.

What is the revenue of Terumo 2024?

The Terumo revenue is 921.86 B JPY.

How high is the profit of Terumo 2024?

The Terumo profit is 106.37 B JPY.

What is the business model of Terumo

The Terumo Corporation is a global company specializing in the development, manufacturing, and marketing of medical technology products. The company is headquartered in Tokyo, Japan and operates worldwide in the fields of cardiology, oncology, radiology, endoscopy, diabetes management, and blood management. One of the core elements of Terumo's business model is continuous research and development of new products. The company invests continuously in the development of medical devices to bring the latest technologies to market and drive innovation. An example of this is the Ultimaster-TF, a medical device for the treatment of heart diseases that is equipped with a special coating for longer-lasting effects and improved treatment efficiency. Terumo also operates an extensive distribution and marketing network to ensure its products are available worldwide. The company collaborates with local partners in various countries and leverages existing networks to sell its products. Terumo also maintains direct business relationships with hospitals, medical centers, and healthcare providers to strengthen its presence in the industry. One of Terumo's main divisions is cardiology. The company offers a wide range of products and services that can be used for the treatment of heart diseases. These include catheters, balloon pumps, and devices for heart-lung machines. Terumo has also developed unique technology that enables the use of heart implants and improves the quality of life for patients with heart diseases. Terumo also has a strong presence in oncology. The company offers a wide range of products and services that can be used for the diagnosis and treatment of cancer. These include catheters, needles, and devices for chemotherapy administration. Terumo has also developed unique technology that allows the direct delivery of drugs to cancer cells to improve treatment effectiveness. Terumo is also involved in the field of radiology. The company offers a wide range of products and services that can be used for the diagnosis and treatment of diseases and injuries, including X-ray and CT machines, as well as contrast agents. Terumo has also developed innovative technologies that improve the accuracy and efficiency of these devices to achieve better outcomes for patients. Terumo is also involved in the field of endoscopy. Here, the company offers a wide range of products and services that can be used for the diagnosis and treatment of digestive system disorders and other internal organ diseases. These include endoscopes, catheters, and mucosectomy devices. Furthermore, Terumo specializes in diabetes management. The company offers a wide range of products and services that can be used for monitoring and regulating blood sugar levels, including insulin pumps and continuous glucose monitoring systems. Terumo has also developed innovative technology that reduces the pain and complications experienced by diabetic patients. Lastly, Terumo is also involved in the field of blood management. The company offers a wide range of products and services that can be used for the diagnosis and treatment of blood disorders, including blood coagulation tests and blood transfusion devices. Terumo has also developed innovative technology that improves the effectiveness and safety of blood transfusions and reduces the risk of infections and other complications. Overall, Terumo is a leading force in the medical industry and offers a wide range of products and services that contribute to improving the health and well-being of people worldwide. Through continuous research and development, global marketing and distribution network, and a solid presence in various medical specialties, the company has a strong business model and positions itself for further growth and success in the future.

What is the Terumo dividend?

Terumo pays a dividend of 37 JPY distributed over 2 payouts per year.

How often does Terumo pay dividends?

Terumo pays out a dividend 2 times a year.

What is the Terumo ISIN?

The ISIN of Terumo is JP3546800008.

What is the Terumo WKN?

The WKN of Terumo is 867003.

What is the Terumo ticker?

The ticker of Terumo is 4543.T.

How much dividend does Terumo pay?

Over the past 12 months, Terumo paid a dividend of 24 JPY . This corresponds to a dividend yield of about 0.84 %. For the coming 12 months, Terumo is expected to pay a dividend of 24.91 JPY.

What is the dividend yield of Terumo?

The current dividend yield of Terumo is 0.84 %.

When does Terumo pay dividends?

Terumo pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Terumo?

Terumo paid dividends every year for the past 23 years.

What is the dividend of Terumo?

For the upcoming 12 months, dividends amounting to 24.91 JPY are expected. This corresponds to a dividend yield of 0.85 %.

In which sector is Terumo located?

Terumo is assigned to the 'Health' sector.

Wann musste ich die Aktien von Terumo kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Terumo from 12/1/2024 amounting to 13 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Terumo pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Terumo in the year 2023?

In the year 2023, Terumo distributed 43 JPY as dividends.

In which currency does Terumo pay out the dividend?

The dividends of Terumo are distributed in JPY.

All fundamentals about Terumo

Our stock analysis for Terumo Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Terumo Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.